Related Experiment Video
Updated: Jun 17, 2026

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
Published on: March 30, 2020
Anti-VEGF therapy for glaucoma
Michael B Horsley1, Malik Y Kahook
1Department of Ophthalmology, Rocky Mountain Lions Eye Institute, University of Colorado School of Medicine, Aurora, Colorado 80045, USA.
Purpose Of Review:
The role of antivascular endothelial growth factor (anti-VEGF) agents in treating various ophthalmic diseases is currently being investigated. There have been many advances in the understanding of how anti-VEGF agents work and speculation on when to implement them clinically for neovascular glaucoma. Recent studies exploring the utility of anti-VEGF agents for wound modulation after trabeculectomy reveal promising results.
Recent Findings:
Anti-VEGF agents have been shown to be beneficial in treating neovascular glaucoma. Their use leads to regression of both iris and angle neovascularization, intraocular pressure control when the angle remains open and, in many cases, prompts symptomatic improvement. In addition, research on the wound modulatory properties of anti-VEGF agents has revealed a dose-dependent inhibition of fibroblast proliferation. Studies exploring the use of anti-VEGF agents at time of trabeculectomy or in bleb revision procedures suggest a beneficial effect on bleb survival and subsequent improvement in intraocular pressure control. Prospective randomized clinical trials are still needed.
Summary:
The recent use of anti-VEGF agents for neovascular glaucoma as well as wound modulation after trabeculectomy has shown great promise. Through future research, the antiangiogenic and antifibroblastic properties of anti-VEGF agents may prove to be beneficial in patients being treated for various forms of glaucoma.
Insights
Antivascular endothelial growth factor (anti-VEGF) agents show promise for treating neovascular glaucoma and improving wound healing after glaucoma surgery. Further research is needed to confirm these benefits in clinical trials.
Area of Science:
- Ophthalmology
- Vascular Biology
- Glaucoma Research
Background:
- Antivascular endothelial growth factor (anti-VEGF) agents are under investigation for ophthalmic applications.
- Understanding of anti-VEGF mechanisms and clinical application in neovascular glaucoma is evolving.
- Emerging research explores anti-VEGF agents for modulating wound healing after trabeculectomy.
Purpose of the Study:
- To review the current role and potential applications of anti-VEGF agents in ophthalmology.
- To evaluate the efficacy of anti-VEGF agents in treating neovascular glaucoma.
- To assess the utility of anti-VEGF agents in wound modulation following glaucoma surgery.
Main Methods:
- Review of recent studies on anti-VEGF agents in ophthalmology.
- Analysis of clinical outcomes in patients with neovascular glaucoma treated with anti-VEGF agents.
- Examination of research on the effects of anti-VEGF agents on fibroblast proliferation and wound healing.
Main Results:
- Anti-VEGF agents effectively reduce neovascularization in the iris and anterior chamber angle.
- Treatment with anti-VEGF agents can lead to intraocular pressure control and symptomatic improvement in neovascular glaucoma.
- Anti-VEGF agents demonstrate dose-dependent inhibition of fibroblast proliferation, suggesting a role in wound modulation.
- Studies indicate potential benefits of anti-VEGF agents in enhancing bleb survival and function after trabeculectomy.
Conclusions:
- Anti-VEGF agents show significant promise for treating neovascular glaucoma and modulating wound healing post-trabeculectomy.
- The antiangiogenic and antifibroblastic properties of anti-VEGF agents may offer therapeutic advantages for various glaucoma conditions.
- Further prospective randomized clinical trials are necessary to solidify the role of anti-VEGF agents in glaucoma management.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Diabetic Retinopathy